PHP
OPRX icon

Parkman Healthcare Partners’s OptimizeRx OPRX Stock Holding History

Parkman Healthcare Partners’s Portfolio OPRX Stock Details OPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.58M Buy
729,369
+190,720
+35% +$1.77M 0.47% 62
2025
Q4 		$6.6M Buy
538,649
+29,038
+6% +$474K 0.63% 50
2025
Q3 		$10.4M Buy
509,611
+2,188
+0.4% +$34.7K 1.09% 33
2025
Q2 		$6.85M Buy
507,423
+32,423
+7% +$355K 0.79% 50
2025
Q1 		$4.11M Buy
+475,000
New +$2.9M 0.49% 59

Other funds holding OPRX

WCA
Whetstone Capital Advisors Shawnee Mission, Kansas $288M AUM 44.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Parkman Healthcare Partners's OPRX Position: Q1 2026 in Review

Parkman Healthcare Partners increased its OptimizeRx (OPRX) stake by 35% in Q1 2026, buying an estimated $1.77M and bringing the position to 729,369 shares worth $4.58M. The position accounts for 0.47% of the portfolio, ranked #62.

Parkman Healthcare Partners first reported a position in OPRX in Q1 2025 and has held it in 5 quarters since. The position peaked at $10.4M in Q3 2025. 127 funds tracked by Wall St. Rank hold OPRX as of Q1 2026.

  • Parkman Healthcare Partners held 729,369 shares of OptimizeRx worth $4.58M as of Q1 2026.
  • Parkman Healthcare Partners bought 190,720 OptimizeRx shares in Q1 2026, an estimated $1.77M.
  • OptimizeRx made up 0.47% of Parkman Healthcare Partners's portfolio in Q1 2026, its #62 holding.
  • Parkman Healthcare Partners first reported a position in OptimizeRx in Q1 2025 and has held it in 5 quarters since.
  • Parkman Healthcare Partners's OptimizeRx position peaked at $10.4M in Q3 2025.
  • 127 funds tracked by Wall St. Rank held OptimizeRx as of Q1 2026.

Based on Parkman Healthcare Partners's 13F filing for Q1 2026, filed 15 May 2026.